A neurology professor talks about the need to identify early biomarkers of MS, describes a three-stage model for the disease, and ponders how to define cure in this setting.
Plasma MTBR-tau243 reflects changes in tau pathology and can be used to stage AD tauopathy and to determine if cognitive symptoms are likely due to AD pathology.
An investigational dual PPAR agonist modifies Alzheimer s pathology and shows cognitive benefit in adults with mild-to-moderate disease and high plasma pTau-217 ratio, early data show.
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy only.